[go: up one dir, main page]

NL300126I1 - Gestabiliseerde farmaceutische formulering die groeihormoon en histidine omvat. - Google Patents

Gestabiliseerde farmaceutische formulering die groeihormoon en histidine omvat.

Info

Publication number
NL300126I1
NL300126I1 NL300126C NL300126C NL300126I1 NL 300126 I1 NL300126 I1 NL 300126I1 NL 300126 C NL300126 C NL 300126C NL 300126 C NL300126 C NL 300126C NL 300126 I1 NL300126 I1 NL 300126I1
Authority
NL
Netherlands
Prior art keywords
histidine
growth hormone
pharmaceutical formulation
stabilized pharmaceutical
includes growth
Prior art date
Application number
NL300126C
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NL300126I1 publication Critical patent/NL300126I1/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NL300126C 1991-12-20 2003-05-01 Gestabiliseerde farmaceutische formulering die groeihormoon en histidine omvat. NL300126I1 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and histidine

Publications (1)

Publication Number Publication Date
NL300126I1 true NL300126I1 (nl) 2003-07-01

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300126C NL300126I1 (nl) 1991-12-20 2003-05-01 Gestabiliseerde farmaceutische formulering die groeihormoon en histidine omvat.

Country Status (24)

Country Link
EP (2) EP0618807B1 (nl)
JP (2) JP2950617B2 (nl)
KR (1) KR100266502B1 (nl)
AT (2) ATE368472T1 (nl)
AU (1) AU667503B2 (nl)
BG (1) BG63075B1 (nl)
CA (1) CA2125855C (nl)
CZ (1) CZ283361B6 (nl)
DE (3) DE10399015I1 (nl)
DK (1) DK0618807T3 (nl)
ES (2) ES2291264T3 (nl)
FI (1) FI115116B (nl)
HU (1) HUT69402A (nl)
IL (1) IL104152A (nl)
MX (1) MX9207374A (nl)
NL (1) NL300126I1 (nl)
NO (1) NO942300L (nl)
NZ (1) NZ246556A (nl)
PT (1) PT618807E (nl)
RO (1) RO111990B1 (nl)
RU (1) RU2122426C1 (nl)
SK (1) SK279641B6 (nl)
UA (1) UA41502C2 (nl)
WO (1) WO1993012812A1 (nl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
ATE184798T1 (de) * 1994-06-17 1999-10-15 Applied Research Systems Hgh enthaltende pharmazeutische zubereitungen
TW426737B (en) * 1994-06-27 2001-03-21 Hayashibara Biochem Lab Saccharide composition with reduced reducibility, and preparation and uses thereof
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
AU4329596A (en) * 1995-01-13 1996-07-31 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
EP1433852B1 (en) 1997-04-09 2006-06-28 Danisco A/S Use of lipase for improving doughs and baked products
CA2309818C (en) * 1997-11-12 2009-05-05 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
KR100890679B1 (ko) 2000-02-24 2009-03-26 일라이 릴리 앤드 캄파니 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
AU2001271491A1 (en) 2000-06-26 2002-01-08 Monsanto Technology Llc Non-aqueous surfactant-containing formulations for extended release of somatotropin
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
WO2002011695A2 (en) 2000-08-07 2002-02-14 Inhale Therapeutic Systems, Inc. Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
EP2311492B1 (en) 2000-08-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing stabilized preparations
ATE362315T1 (de) 2001-05-18 2007-06-15 Danisco Verfahren zur herstellung von teig mit einem enzym
AU2003300126B2 (en) * 2002-12-31 2010-04-01 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
SG176314A1 (en) 2002-12-31 2011-12-29 Altus Pharmaceuticals Inc Human growth hormone crystals and methods for preparing them
MXPA05007653A (es) 2003-01-17 2005-09-30 Danisco Metodo.
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
GB0405637D0 (en) 2004-03-12 2004-04-21 Danisco Protein
EP2267107A3 (en) 2004-07-16 2011-05-25 Danisco A/S Lipolytic Enzyme. Uses Thereof In The Food Industry
ES2504441T3 (es) * 2004-12-15 2014-10-08 Swedish Orphan Biovitrum Ab (Publ) Formulaciones terapéuticas del factor de crecimiento de queratinocitos
CA2594561C (en) * 2004-12-22 2014-12-23 Ambrx, Inc. Formulations of human growth hormone comprising a non-naturally encoded amino acid
KR20080038391A (ko) * 2005-08-30 2008-05-06 노보 노르디스크 헬스 케어 악티엔게젤샤프트 페그화 성장 호르몬의 액체 제제
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
EP2505593A1 (en) 2005-12-28 2012-10-03 Novo Nordisk A/S Compositions comprising an acylated insulin and zinc and method of making the said compositions
KR20100014215A (ko) 2006-07-07 2010-02-10 노보 노르디스크 헬스 케어 악티엔게젤샤프트 신규 단백질 접합체 및 그것의 제조 방법
EP2120869A2 (en) * 2006-12-18 2009-11-25 Altus Pharmaceuticals Inc. Human growth hormone formulations
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
DK3608330T3 (da) * 2008-12-16 2023-02-06 Genzyme Corp Syntetiske mellemprodukter til fremstilling af oligosaccharid-protein-konjugater
US9238878B2 (en) 2009-02-17 2016-01-19 Redwood Bioscience, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
PH12012501252A1 (en) 2009-12-21 2012-11-05 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
US8765411B2 (en) * 2010-09-21 2014-07-01 Ferring B.V. Process for production of recombinant human growth hormone from E. coli cells
HRP20191793T1 (hr) 2010-10-27 2019-12-27 Novo Nordisk A/S Liječenje dijabetesa melitusa injekcijama inzulina koje se primijenjuje u različitim intervalima injiciranja
KR20140016262A (ko) 2011-01-14 2014-02-07 레드우드 바이오사이언스 인코포레이티드 알데하이드-태깅된 면역글로불린 폴리펩타이드 및 이의 사용 방법
RU2688672C2 (ru) 2012-06-05 2019-05-22 Неуродерм Лтд Композиции, содержащие апоморфин и органические кислоты, и их применение
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN108367094B (zh) * 2015-12-10 2021-09-14 株式会社目立康 肽组合物
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
BR112020023860A2 (pt) * 2018-05-25 2021-04-13 Dr. Reddy's Laboratories Ltd. Formulação estável de proteína de fusão, e, métodos para obter uma formulação estável e para aumentar a estabilidade de proteína de fusão
WO2020004368A1 (ja) * 2018-06-25 2020-01-02 Ｊｃｒファーマ株式会社 蛋白質含有水性液剤
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR20250024094A (ko) 2018-10-26 2025-02-18 노보 노르디스크 에이/에스 안정한 세마글루티드 조성물 및 이의 용도
WO2021009027A1 (en) 2019-07-12 2021-01-21 Novo Nordisk A/S High concentration insulin formulation
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
DK168790D0 (nl) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
KR100266502B1 (ko) 2000-09-15
FI942906L (fi) 1994-06-17
WO1993012812A1 (en) 1993-07-08
RU94045932A (ru) 1997-04-20
DE69233704D1 (de) 2007-09-13
DK0618807T3 (da) 2003-03-03
EP0618807B1 (en) 2002-11-13
DE10399015I2 (de) 2008-08-07
EP1197222B1 (en) 2007-08-01
DE69233704T2 (de) 2008-05-21
CA2125855A1 (en) 1993-07-08
RO111990B1 (ro) 1997-04-30
SK75494A3 (en) 1995-03-08
MX9207374A (es) 1993-07-01
CZ283361B6 (cs) 1998-03-18
SK279641B6 (sk) 1999-01-11
JP2950617B2 (ja) 1999-09-20
UA41502C2 (uk) 2001-09-17
CZ150794A3 (en) 1995-01-18
EP1197222A3 (en) 2004-02-04
EP1197222A2 (en) 2002-04-17
ATE368472T1 (de) 2007-08-15
JPH11315031A (ja) 1999-11-16
RU2122426C1 (ru) 1998-11-27
ATE227583T1 (de) 2002-11-15
CA2125855C (en) 2008-05-13
NO942300D0 (no) 1994-06-17
ES2291264T3 (es) 2008-03-01
ES2185625T3 (es) 2003-05-01
IL104152A (en) 1998-06-15
BG98806A (bg) 1995-02-28
AU667503B2 (en) 1996-03-28
NO942300L (no) 1994-08-19
AU3344693A (en) 1993-07-28
DE10399015I1 (de) 2012-05-03
EP0618807A1 (en) 1994-10-12
IL104152A0 (en) 1993-05-13
NZ246556A (en) 1996-03-26
FI942906A0 (fi) 1994-06-17
HU9401832D0 (en) 1994-09-28
PT618807E (pt) 2003-03-31
DE69232847D1 (de) 2002-12-19
DE69232847T2 (de) 2003-09-11
BG63075B1 (bg) 2001-03-30
HUT69402A (en) 1995-09-28
JPH07502516A (ja) 1995-03-16
FI115116B (fi) 2005-03-15

Similar Documents

Publication Publication Date Title
NL300126I1 (nl) Gestabiliseerde farmaceutische formulering die groeihormoon en histidine omvat.
DE69228704D1 (de) Stabilisierte pharmazeutische formulierung, die wachstumshormon und asparagin enthält
CA2037884A1 (en) Stabilized gonadotropin containing preparations
IL115590A (en) Pharmaceutical formulation comprising a growth hormone and isoleucine
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
NO980103L (no) Stabilisert farmasöytisk preparat som omfatter et veksthormon og et peptid omfattende minst én basisk aminosyrerest og minst én sur aminosyrerest